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High-Density Lipoprotein
Particle Number
A Better Measure to Quantify
High-Density Lipoprotein?*
Emil M. deGoma, MD,† Daniel J. Rader, MD‡
Philadelphia, Pennsylvania
Limitations in our ability to predict cardiovascular risk have
fueled efforts to identify novel risk markers and to refine the
measurement of traditional risk factors, such as low-density
lipoprotein cholesterol (LDL-C) and high-density lipopro-
tein cholesterol (HDL-C). Standard assays to evaluate
LDL-C and HDL-C quantify the cholesterol content
within the respective lipoprotein fraction. However, both
LDL and HDL particles vary in their content of cholesterol,
and thus determining the concentration of lipoprotein
See page 508
particles themselves may be superior to counting choles-
terol cargo in assessing cardiovascular risk. For example,
there is 1 molecule of apolipoprotein B (apo B) per
low-density lipoprotein-particle (LDL-P) and, thus,
plasma concentrations of apo B more closely reflect
LDL-P concentrations than levels of LDL-C. Some
(1,2), but not all (3), prospective population studies
indicate a stronger association between apo B and car-
diovascular events than between LDL-C and cardiovas-
cular events.
Another approach to quantitation of lipoprotein particle
concentrations utilizes nuclear magnetic resonance (NMR)
spectroscopy. This method takes advantage of 2 important
principles to permit rapid quantification of lipoprotein
concentrations without requiring physical separation (4).
First, each lipoprotein subclass emits a distinct signal when
subjected to electromagnetic pulses in a magnetic field;
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Strategies.second, the signal amplitudes generated are directly propor-
tional to the concentration of the particles emitting the
signal. Using a library of known lipids, sample signals can be
deconvoluted to determine concentrations of individual
lipoprotein subclasses. There is now abundant literature on
the quantitation of LDL-P number by NMR spectroscopy
and association with cardiovascular events, and in most
cases LDL-P outperforms LDL-C in predicting cardiovas-
cular risk. Moreover, limited data comparing LDL-C and
LDL-P in the setting of discordance—when the 2 measures
differ substantially—indicate a more robust association of
the latter with cardiovascular events and surrogate imaging
markers. In an analysis of the Framingham cohort, event-
free survival tracked LDL-P and not LDL-C when the 2
were discordant (5). Similarly, in a previous examination of
the MESA (Multi-Ethnic Study of Atherosclerosis),
LDL-P proved a more reliable predictor of carotid intima-
media thickness (cIMT) than LDL-C when the 2 values
differed (6).
The report by Mackey et al. (7) in this issue of the Journal
extends the lipoprotein cholesterol content versus lipopro-
tein particle number debate to HDL. The authors suggest
that NMR-derived HDL particle (HDL-P) number may
serve as a better method than HDL-C to assess cardiovas-
cular risk. Leveraging the diverse and well-characterized
MESA cohort, Mackey et al. (7) studied 5,598 men and
women without known coronary heart disease (CHD) or
lipid-lowering therapy reported at baseline. The authors
evaluated the associations of baseline HDL-C and HDL-P
number determined by NMR spectroscopy with maximal
cIMT, a validated surrogate marker of atherothrombotic
risk, and coronary events (myocardial infarction, CHD
death, angina) after a mean follow-up of 6 years. After
adjusting for age, sex, ethnicity, hypertension, and smoking,
Mackey et al. (7) calculated, per 1-SD increase in HDL-C
or HDL-P, a decrease in cIMT of 0.026 mm (95%
confidence interval [CI]: 0.017 to 0.035 mm) and 0.030 mm
(95% CI: 0.021 to 0.039 mm), and a reduction in CHD risk
of 26% (95% CI: 12% to 37%) and 30% (95% CI 18% to
41%), respectively. Although associations between HDL-C
and HDL-P and cardiovascular endpoints were similar in
standard multivariable-adjusted models, the novel and im-
portant contribution of this report was found after adjusting
each HDL metric for the other and for LDL-P. Joint
analysis revealed that the inverse relationship between
HDL-P and cardiovascular risk persisted after controlling
for HDL-C and LDL-P, with a 1-SD increase in HDL-P
associated with a decrease in cIMT of 0.022 mm (95% CI:
0.011 to 0.034 mm) and a reduction in CHD risk of 25%
(95% CI: 7% to 39%). In contrast, HDL-C was neither
associated with cIMT nor CHD risk after incorporating
HDL-P and LDL-P into the model.
The results of Mackey et al. (7) are consistent with previous
findings from the EPIC (European Prospective Investigation
into Cancer and Nutrition)-Norfolk population-based pro-
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Quantifying HDL August 7, 2012:517–20spective study (6). A case-control analysis demonstrated a
consistent association between HDL-P and coronary artery
disease (CAD) risk after adjusting for traditional, metabolic,
and inflammatory risk factors as well as mean HDL size
assessed by NMR (top vs. bottom quartile, odds ratio [OR]
0.50; 95% CI: 0.37 to 0.66, p  0.001). Although adjust-
ment for HDL-C was not reported, the close correlation
between HDL size and HDL-C (Pearson correlation coef-
ficient 0.76, p  0.001) suggested that an independent
ssociation between HDL-P and CAD risk might remain
ven after adjustment for HDL-C. In contrast, the MESA
ndings disagreed with previous results of the Women’s
ealth Study (WHS) (8). In the trial involving 27,673
ealthy women followed over an 11-year period, HDL-P
as not associated with incident cardiovascular disease after
djustment for age, randomized treatment assignment,
moking status, menopausal status, postmenopausal hor-
one use, blood pressure, diabetes mellitus, and body mass
ndex (top vs. bottom quintile, hazard ratio [HR]: 0.91; 95%
I: 0.71 to 1.12, p  0.34). WHS differed from MESA in
ts exclusive focus on women, who comprised 53% of
ESA participants, and in the randomized design, which
valuated low-dose aspirin and vitamin E. Importantly,
evels of HDL-P subfractions were substantially different
etween the 2 studies, which might explain the conflicting
esults.
The consistent association observed in the MESA anal-
sis between HDL-P and cardiovascular events even after
ontrolling for HDL-C raises several important questions.
. For which patients might HDL-P measurement be
reasonable to refine cardiovascular risk? Establishing the
clinical utility of HDL-P requires more than an inde-
pendent association with cIMT or cardiovascular out-
comes. Calibration, discrimination, and reclassification
analyses are needed to further clarify the role of HDL-P
above and beyond traditional risk factors. Highlighting
the incremental prognostic value of HDL-P in the
setting of discordance between HDL-P and HDL-C—
higher (or lower) HDL-P values than expected for given
HDL-C levels— might better focus such examination.
The prevalence of and clinical phenotypes associated
with discrepant HDL-P and HDL-C also need to be
clarified.
. What is the relationship between HDL-P and apolipo-
protein A-I (apo A-I)? Apo A-I is the primary protein
constituent of HDL, accounting for 70% of total HDL
protein. In numerous epidemiological studies, levels of
apo A-I demonstrated an inverse relationship to cardio-
vascular risk, sometimes greater than that for HDL-C
(1,9,10). Importantly, apo A-I is not synonymous with
the concentration of HDL-P. Large, spherical HDL-P
carry 4 to 5 apo A-I molecules, whereas small discoidal
HDL bear 2 to 3 molecules (11). As a result, the
correlation between apo A-I and HDL-P number is
imperfect, with coefficients of 0.54 and 0.69 observed inthe EPIC-Norfolk cohort and the WHS, respectively
(6,8). Given the inconsistent relationship between apo
A-I and HDL-P, it is surprising that previous analyses of
2 different cohorts yielded nearly identical results to the
MESA study using apo A-I instead of HDL-P. In a
case-control study of the EPIC-Norfolk cohort (12),
HDL-C was no longer predictive of CAD risk after
adjustment for apo A-I and apo B (per 1-SD increase,
OR: 1.07, 95% CI: 0.89 to 1.28, p  0.49). However,
apo A-I remained significantly associated with CAD risk
even after adjusting for HDL-C and apo B (per 1-SD
increase, OR: 0.74, 95% CI: 0.62 to 0.88, p  0.001) or
HDL size and apo B (per 1-SD increase, OR: 0.69, 95%
CI: 0.61 to 0.79; p 0.0001). Similar results were found
in a post hoc analysis of the IDEAL (Incremental
Decrease in End Points through Aggressive Lipid Low-
ering) trial, a randomized trial comparing atorvastatin 80
and simvastatin 20 mg/day (12). After adjustment for
apo A-I and apo B, HDL-C became positively associ-
ated with CAD (per 1-SD increase, risk ratio [RR]:
1.21, 95% CI: 1.01 to 1.46, p  0.04). In contrast, apo
A-I remained inversely associated with CAD even after
adjustment for HDL-C and apo B (per 1-SD increase,
RR: 0.74, 95% CI: 0.61 to 0.90, p  0.002).
Unfortunately, apo A-I (and apo B) data were unavail-
able for the MESA cohort, and only 1 large prospective
study examined both apo A-I and HDL-P levels (8). In the
WHS, unlike HDL-P, HDL-C and apo A-I were in-
versely associated with incident cardiovascular disease after
multivariable adjustment (HDL-C quintile 5 vs. quintile 1,
HR: 0.53, 95% CI: 0.42 to 0.64, p  0.001; apo A-I
quintile 5 vs. quintile 1, HR: 0.63, 95% CI: 0.52 to 0.77,
p  0.001). Future research would benefit from simulta-
neously acquired apo A-I and HDL-P data to compare
their relationship with cardiovascular risk, including after
adjustment for HDL-C.
. What is the biological explanation for the more robust
association between HDL-P and cardiovascular risk?
Identifying which aspects of HDL functionality are
uniquely captured by HDL-P and not HDL-C repre-
sents an important next step. Recent publications shed
light on promising assays that measure reverse choles-
terol transport and anti-inflammatory activity. One study
utilized a validated ex vivo system to quantify cholesterol
efflux capacity using incubation of macrophages with apo
B-depleted serum (13). Healthy participants exhibited
an inverse relationship between efflux capacity and cIMT
before and after adjustment for HDL-C. Among sub-
jects who underwent coronary angiography for clinically
suspected CHD, efflux capacity remained a strong in-
verse predictor of coronary disease status after adjust-
ment for traditional risk factors as well as HDL-C
(adjusted OR for CAD per 1-SD increase in efflux
capacity: 0.75; 95% CI: 0.63 to 0.90) and apo A-I (OR:
0.74; 95% CI: 0.61 to 0.89). A second study demon-
strated an association between coronary disease status
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quantified as the ratio of in vitro LDL oxidation of a
fluorescein substrate incubated with and without partic-
ipant HDL (14). Among 193 symptomatic patients who
underwent angiography, HII was significantly higher
(less antioxidant capacity) among those with acute cor-
onary syndrome (ACS) than those without CAD (1.57
vs. 1.17, p  0.005) or with stable CAD (1.57 vs. 1.11,
p  0.006). Association with ACS remained significant
after adjusting for traditional risk factors (OR 3.8, p 
0.003). Studies incorporating both HDL-P assessment
and functional assays such as cholesterol efflux or anti-
inflammatory activity are needed to better understand
the physiological basis of the more reliable association
between HDL-P and cardiovascular outcomes.
4. Can HDL-P serve as a more reliable surrogate marker of
antiatherogenic potential for HDL-directed therapies in
development? In the setting of HDL-directed therapies,
a consistent inverse relationship between HDL-C and
cardiovascular risk can no longer be assumed (15).
Reliable surrogate markers are needed to facilitate the
development of novel HDL therapies. As previously
discussed, assays that measure specific dimensions of
HDL functionality are being evaluated. Physicochemical
measures of HDL-P, such as quantity, size, and compo-
sition, represent a second type of surrogate marker that
may serve as proxies for function and, in turn, anti-
atherogenic potential (16). Assays to determine these
intrinsic HDL characteristics generally benefit from
greater ease and precision than methods to interrogate
HDL function, facilitating use in large population stud-
ies and clinical trials. Although the study of Mackey et al.
(7) was not an intervention study—participants on lipid-
lowering therapy were excluded—the independent asso-
ciation of HDL-P with cardiovascular events suggests
that HDL-P may serve as a useful tool to assess
HDL-directed pharmacotherapies. Moreover, the find-
ings suggest that increasing HDL-P levels may be more
desirable than augmenting HDL-C levels. To date, few
studies have examined the effect of existing and emerging
HDL-targeted drugs on HDL-P. In a post hoc analysis
of the VA-HIT (Veterans Affairs High-Density Lipo-
protein Intervention Trial), a randomized, placebo-
controlled trial of gemfibrozil among men with CHD,
on-treatment HDL-P was strongly associated with
CHD events (OR: 0.71, 95% CI: 0.61 to 0.81, p 
0.0001), whereas HDL-C was not (OR: 0.95, 95% CI:
0.83 to 1.08, p  0.42). Extended-release niacin 2000
mg/day increased both HDL-C and total HDL-P by
23% after 12 weeks of use (17). The relationship between
niacin, HDL-P, and cardiovascular endpoints has not
been elucidated; changes in HDL-P in the recently
reported AIM-HIGH (Atherothrombosis Intervention
in Metabolic syndrome with low HDL/high triglycer-
ides: Impact on Global Health outcomes) trial (18) that
failed to show benefit of niacin in reducing cardiovascu-lar events would be of interest. Changes in total HDL-P
with administration of cholesteryl ester transfer protein
inhibitors have not been reported in the published
literature. Further studies are needed to assess changes in
HDL-P resulting from HDL-directed therapies and to
determine whether the inverse relationship between
HDL-P and cardiovascular outcomes persists in the
context of these interventions.
In summary, the study of Mackey et al. (7) demonstrated
more consistent inverse association between cardiovascular
ndpoints and NMR-derived HDL-P compared with
DL-C. These findings suggest that direct quantification
f the concentration of HDL-P may be useful to refine
ardiovascular risk and to evaluate novel HDL-directed
herapies. Further studies are needed to clarify the role of
DL-P in clinical practice.
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